Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma


Disclosures: EMO discloses the following outside the present work: Research support from Amgen, Array Pharmaceuticals, Celgene, IDP-Pharma and Mundipharma-EDO. Honoraria from Amgen, BMS, Celgene, Janssen, Takeda, Tecnofarma and Novartis Onc. Consultancy from Amgen, Celgene, Janssen, Mundipharma-EDO, Oncopetides, Takeda, Bayer, Pharmamar, AbbVie, Novartis Onc., Seattle Genetics. Speaker’s bureau from Takeda and Janssen. Educational support (meetings attendance) from Celgene, Janssen, Takeda and Novartis Onc. MVM has received honoraria from lectures from Janssen, Celgene, Takeda and Amgen. MVM has received honoraria from participation in advisory boards from Janssen, Celgene, Amgen, Takeda, Abbvie, GSK and Pharmamar. MVM has received support for assistance to congress from Janssen, Celgene and Amgen. NCG discloses honoraria from Janssen. MS, SB, LKB, IK and AD are employees of Institut de Recherches Servier. EH and HM are employees of Novartis Institutes for Biomedical Research. The remaining authors declare no competing interests. We attest that we have herein disclosed any and all financial or other relationships that could be construed as a conflict of interest, and that all sources of financial support for this study have been disclosed and are indicated in the Acknowledgements section.

Contributions: EMA, MG and EMO designed research and wrote the paper. EMA, ADT, PM, SHG, LAC, LSS, MMS, LGM and TP performed experiments and analyzed the data. MS, SB, LKB, IK, AD, EH and HM provided research tools. NCG, MVM and EMO provided clinical samples and contributed to the clinical data. All authors reviewed and approved the manuscript.